Efficacy and safety of switching from bosentan or ambrisentan to macitentan in pulmonary arterial hypertension: A systematic review and meta-analysis

MLA

Jie Li, et al. “Efficacy and Safety of Switching from Bosentan or Ambrisentan to Macitentan in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis.” Frontiers in Cardiovascular Medicine, vol. 9, Dec. 2022. EBSCOhost, https://doi.org/10.3389/fcvm.2022.977110.

APA

Jie Li, Zu-Yuan Yang, Shang Wang, Ping Yuan, Qin-Hua Zhao, Su-Gang Gong, Hong-Ling Qiu, Ci-Jun Luo, Hui-Ting Li, Rui Zhang, Wen-Hui Wu, Jin-Ming Liu, Lan Wang, Shan-Shan Liu, & Rong Jiang. (2022). Efficacy and safety of switching from bosentan or ambrisentan to macitentan in pulmonary arterial hypertension: A systematic review and meta-analysis. Frontiers in Cardiovascular Medicine, 9. https://doi.org/10.3389/fcvm.2022.977110

Chicago

Jie Li, Zu-Yuan Yang, Shang Wang, Ping Yuan, Qin-Hua Zhao, Su-Gang Gong, Hong-Ling Qiu, et al. 2022. “Efficacy and Safety of Switching from Bosentan or Ambrisentan to Macitentan in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis.” Frontiers in Cardiovascular Medicine 9 (December). doi:10.3389/fcvm.2022.977110.